» Articles » PMID: 29616113

Clinical Significance of High Expression of MiR-452-5p in Lung Squamous Cell Carcinoma

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Apr 5
PMID 29616113
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The role of microRNA (miRNA)-452-5p in lung squamous cell carcinoma (LUSC) remains unclear. Therefore, the present systematic study was performed to investigate the clinical significance and the rudimentary mechanism of the function of miR-452-5p in LUSC. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to confirm the expression level and clinical value of miR-452-5p in LUSC. Using online databases and bioinformatic software, gene ontology (GO), pathway and protein-protein interaction (PPI) analyses of miR-452-5p target genes were performed to examine the molecular mechanism of miR-452-5p. The association between the expression of miR-452-5p and that of its hub genes was verified using TCGA. Based on TCGA data on 387 clinical specimens, the expression of miR-452-5p in LUSC was significantly increased compared with adjacent lung tissues (7.1525±1.39063 vs. 6.0885±0.35298; P<0.001). The expression levels of miR-452-5p were significantly correlated with age (P=0.001) and tumor-node metastasis stage (P=0.028). Furthermore, the increased expression of miR-452-5p in LUSC compared with non-cancerous tissue [standard mean deviation (SMD), 0.372; 95% confidence interval (CI), 0.020-0.724; z=2.07; P=0.038] was validated by a meta-analysis of 720 clinical samples. The GO and pathway analyses revealed that miR-452-5p target genes were mainly enriched in the 'regulation of transcription', 'nucleoplasm', 'protein binding' and 'cell cycle' pathways. A total of 10 hub genes were identified by PPI analysis, and 5 hub genes (SMAD4, SMAD2, CDKN1B, YWHAE and YWHAB) were significantly enriched in the 'cell cycle' pathway. The expression of CDKN1B was negatively correlated with miR-452-5p (P=0.003). It was concluded that miR-452-5p may serve an essential role in the occurrence and progression of LUSC by targeting CDKN1B, which is involved in the cell cycle.

Citing Articles

The RNA binding protein IGF2BP2/IMP2 alters the cargo of cancer cell-derived extracellular vesicles supporting tumor-associated macrophages.

Mashayekhi V, Schomisch A, Rasheed S, Aparicio-Puerta E, Risch T, Yildiz D Cell Commun Signal. 2024; 22(1):344.

PMID: 38937789 PMC: 11212187. DOI: 10.1186/s12964-024-01701-y.


CircCCDC66: Emerging roles and potential clinical values in malignant tumors.

Wang X, Zhang C, Song H, Yuan J, Zhang L, He J Front Oncol. 2023; 12:1061007.

PMID: 36698408 PMC: 9869039. DOI: 10.3389/fonc.2022.1061007.


MicroRNA-452: a double-edged sword in multiple human cancers.

Dermani F, Datta I, Khoei S Clin Transl Oncol. 2023; 25(5):1189-1206.

PMID: 36622551 DOI: 10.1007/s12094-022-03041-0.


LINC01140 Targeting miR-452-5p/RGS2 Pathway to Attenuate Breast Cancer Tumorigenesis.

Li X Dis Markers. 2022; 2022:2434938.

PMID: 36299824 PMC: 9592237. DOI: 10.1155/2022/2434938.


MAGI2-AS3 restrains proliferation, glycolysis, and triggers apoptosis in acute lymphoblastic leukemia via regulating miR-452-5p/FOXN3 pathway.

Chen X, Dou B, An J, Feng S, Liu N, Sheng G Iran J Basic Med Sci. 2022; 25(1):46-52.

PMID: 35656441 PMC: 9118285. DOI: 10.22038/IJBMS.2021.58963.13095.


References
1.
Zou Z, Fan L, Wang L, Xu J, Zhang R, Tian T . miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. Oncotarget. 2014; 6(2):1276-85. PMC: 4359232. DOI: 10.18632/oncotarget.2626. View

2.
Liu Y, Miao L, Ni R, Zhang H, Li L, Wang X . microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. Oncol Rep. 2016; 36(6):3529-3535. DOI: 10.3892/or.2016.5149. View

3.
Li D, Du X, Liu A, Li P . Suppression of nucleosome-binding protein 1 by miR-326 impedes cell proliferation and invasion in non-small cell lung cancer cells. Oncol Rep. 2015; 35(2):1117-24. DOI: 10.3892/or.2015.4403. View

4.
Hu M, Hu Y, He J, Li B . Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis. PLoS One. 2016; 11(1):e0147374. PMC: 4732945. DOI: 10.1371/journal.pone.0147374. View

5.
Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V, Fleischhacker M . Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS One. 2015; 10(2):e0118195. PMC: 4326280. DOI: 10.1371/journal.pone.0118195. View